Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended September 30, 2026 (Q2 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results
Audit Opinion (clearly state if Qualified, Modified, or Clean):
Unmodified opinion with Emphasis of Matter regarding going concern uncertainty
Auditor's Comment (highlight if it affects earnings quality, internal controls, or going concern):
Auditors drew attention to Note No. 8 regarding classification of borrowings from two consortium banks as Non-Performing Assets, demand notice dated 23 September 2026 issued by Bank of Baroda under Section 13(2) of the SARFAESI Act, 2002, and excess of current liabilities over current assets as at 30 September 2026. These conditions indicate material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern.
Key Financial Highlights [₹ in Lakhs]:
Standalone Results:
Revenue from Operations: ₹7,939.24 (Q2 FY27) vs ₹4,926.05 (Q2 FY26) - 61.2% YoY increase
Total Income: ₹7,956.06 (Q2 FY27) vs ₹4,957.19 (Q2 FY26) - 60.5% YoY increase
Net Profit/(Loss): (₹720.93) (Q2 FY27) vs (₹724.64) (Q2 FY26)
EPS: (₹4.55) (Q2 FY27) vs (₹4.58) (Q2 FY26)
Other Equity: ₹7,244.78 (as at 30.09.2026) vs ₹8,749.35 (as at 31.03.2026)
Cash and Cash Equivalents: ₹80.56 (as at 30.09.2026) vs ₹67.25 (as at 31.03.2026)
Debt: Total borrowings ₹8,804.14 (₹8,284.94 current + ₹519.20 non-current) as at 30.09.2026
Consolidated Results:
Revenue from Operations: ₹7,939.24 (Q2 FY27) vs ₹4,926.05 (Q2 FY26) - 61.2% YoY increase
Total Income: ₹7,956.06 (Q2 FY27) vs ₹4,957.19 (Q2 FY26) - 60.5% YoY increase
Net Profit/(Loss): (₹720.81) (Q2 FY27) vs (₹734.63) (Q2 FY26)
EPS: (₹4.55) (Q2 FY27) vs (₹4.64) (Q2 FY26)
Other Equity: ₹7,210.07 (as at 30.09.2026) vs ₹8,723.08 (as at 31.03.2026)
Cash and Cash Equivalents: ₹83.51 (as at 30.09.2026) vs ₹70.10 (as at 31.03.2026)
Debt: Total borrowings ₹8,804.13 (₹8,284.93 current + ₹519.20 non-current) as at 30.09.2026
Segment-wise Performance:
The Company's business activity falls within a single reportable Business Segment: 'Manufacturing of Bulk Drugs'
Corporate Actions:
No dividend declarations, share splits, bonus issues, buybacks, or capital raising activities announced.
Other Significant Information:
- Scheme of Merger by Absorption of Mangalam Laboratories Private Limited and Shri J& Pharma Private Limited with Mangalam Drugs approved by Board on March 15, 2024, yet to be heard by NCLT
- Company has recognized deferred tax asset on tax losses based on projections
- Power and Fuel Expenses: ₹568.07 lakhs (Q2 FY27)
- Paid-up Equity Share Capital: ₹1,582.82 lakhs (Face value ₹10 per share)
- Manufacturing units at Vapi (Gujarat) and Mumbai
Entities included in consolidation:
Mangalam Laboratories Private Limited (subsidiary) - not material subsidiary
Total revenues: ₹32.10 lakhs for quarter and half year ended 30 September 2026
Total net loss after tax: ₹8.41 lakhs for quarter and half year ended 30 September 2026